A Medical Device Daily
Regent Medical Americas (Norcross, Georgia), the North American arm of Regent Medical (Gotheberg, Sweden), a medical glove company with an exclusively powder-free glove line, reported completing Regent Medical's merger with Molnlycke Health Care and Medlock Medical (both Gotheburg), creating a new medical products group, Molnlycke Health Care Group .
Lundy Fields, formerly president of Regent Medical Americas and now Molnlycke Health Care U.S. president, said the merger results in a new force in global healthcare. “The compelling strategic fit between Molnlycke and Regent, a leading surgical supplier known for its two brands – Biogel powder-free surgical gloves and Hibiclens antiseptic/antimicrobial skin cleanser, and Medlock, a niche wound care company, creates a company with a significantly enhanced product range and opportunity in the market.”
The company's two divisions will be Surgical and Wound Care. Focusing on prevention of surgically-related infections for both patients and healthcare workers, the Surgical Division will encompass a manufacturer and supplier of powder-free surgical gloves (Biogel surgical gloves) and the No. 1 supplier (by value) of skin cleanser (Hibiclens and Hibistat antiseptics).
Molnlycke CEO John Samuel said, “The platform for future growth is in place and now it is time for us to focus on improving and expanding our business. Our strategy is two-fold: In Surgical, we plan to take advantage of the growing market need for single use products and further expand geographically; and in Wound Care, we plan to grow the advanced wound care business from the strong base of the market leading Safetac technology both with innovative new products and further geographical spread.”
Novasys Medical (Newark, New Jersey) said it has agreed to acquire certain patents from Curon Medical (Fremont, California) for $650,000 in cash. Novasy has secured the rights to use certain intellectual property of Curon for the treatment of urinary incontinence and other genito-urinary conditions in men and women.
Larry Heaton II, president and CEO of Curon, said, “As the IP involved is unrelated to Curon's core business, this transaction will have no adverse impact on our applications of radiofrequency energy for the treatment of gastroesophageal reflux disease or bowel incontinence.”
Debra Reisenthel, president and CEO of Novasys, said, “With the recent successful launch of our Renessa System for the treatment of stress urinary incontinence in women, we are looking to future development opportunities as well. The IP licensed from Curon will assist us in expanding the potential applications for our core technology for the treatment of various genito-urinary conditions in both women and men.”
Curon's products and products under development consist of radio frequency generators and single use disposable devices.
Novasys specializes in developing therapies in women's health.